|Description||An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations.|
|Brife Description||IPI-493 is a potent and orally bioavailable Hsp90 inhibitor with Ki of 21 nM.|
|Synonyms||IPI493; IPI 493; NSC 255109; 17-Aminogeldanamycin; 17-Amino Geldanamycin; 17-Aminodemethoxygeldanamycin; 17-Amino-17-demethoxygeldanamycin|
|Storage||at -20°C 2 years|
Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhib...
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
NVP-BEP800 is a novel, fully synthetic Hsp90β inhibitor with IC50 of 58 nM, exhibits >70-fold selectivity against Hsp90 family members Grp94 and Trap-1.
Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth
NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.
SNX-7081 is a novel small molecule inhibitor of Hsp90. SNX-7081 showed strong binding affinity to Hsp90 and expected induction of Hsp70. NF-kappaB nuclear trans...
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
CCT018159 is a novel inhibitor of heat shock protein (Hsp) 90 with potential anticancer activity. CCT018159 inhibited human Hsp90beta with comparable potency to...
WK88-1 inhibits Hsp90, resulting in decreased expression of Hsp90 client proteins and potentially leading to decreased tumor cell growth.
Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.
17-AAG is an orally bioavailable, small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activit...
Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 by binding to the ATP-binding site.IC50 = 2μM. Exhibits antitumor and cytocidal activities (I...
Derrubone is a prenylated isoflavone, a type of flavonoid. It was originally isolated from the Indian tree Derris robusta.It has potential application as an inh...
Coumemycin A1 is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 70μmol...
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
PF-04929113, also known as SNX-5422; is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although t...
VER-50589 is a potent Hsp90 inhibitor with IC50 of 21 nM for Hsp90β.
An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhi...
TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...